On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a ...

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

The Bilateral Indigenous Patient ... The program is intended to improve Indigenous patient access and experiences when accessing the primary health care system by: supporting the provision of cultural ...

and the new headwind in the form of Medicare Part D benefit design which represents an additional headwind AbbVie needs to absorb. The pipeline is also progressing nicely. There are five new ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...

AbbVie reported its 2024 Q4 results on Friday. Investors especially liked the drugmaker's 2025 outlook. AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher than the average ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...

The patient must have six months or less to live ... When asked about people who think dying with medical assistance isn't a great idea, Goodfriend said, "If it's not a good idea for you, don ...

White House press secretary Karoline Leavitt answered questions about the Trump administration’s decision to suspend federal aid to several assistance programs. Photo: Roberto Schmidt/AFP/Getty ...

The Trump administration’s orders have sent a chill through humanitarian organizations in Ukraine, which depend heavily on such assistance. By Maria Varenikova and Constant Méheut Reporting ...